Last update 30 May 2025

(-)-Epigallocatechin Gallate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(-)-epi-gallocatechin-3-gallate, EGCG, Epigallocatechin gallate
+ [4]
Action
inhibitors
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors), α-synuclein inhibitors(Synuclein alpha inhibitors)
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18O11
InChIKeyWMBWREPUVVBILR-WIYYLYMNSA-N
CAS Registry989-51-5

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Muscular Dystrophy, DuchennePhase 3
Germany
30 Dec 2010
Alzheimer DiseasePhase 3
Germany
01 Oct 2009
Brain atrophyPhase 3
Germany
-01 May 2009
Multiple Sclerosis, Chronic ProgressivePhase 3
Germany
-01 May 2009
Hepatocellular CarcinomaPhase 2
United States
01 Sep 2024
Liver CirrhosisPhase 2
United States
01 Sep 2024
Huntington DiseasePhase 2
Germany
01 Sep 2011
Multiple Sclerosis, Relapsing-RemittingPhase 2
Germany
01 Sep 2007
Inflammatory Bowel DiseasesPreclinical
United States
10 Aug 2024
Myocardial IschemiaPreclinical
China
01 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
54
swwqlmuwft(lpenilhwdo) = ebhqmqtzbi vfpqpgadwo (bqygjsnbhp )
Positive
17 Apr 2024
Phase 3
92
(EGCG as Putative Neuroprotective Agent)
ehvhxrxqrm(cymlbeaqvh) = svntuezjwc beihtowupm (eccmzalfxx, 1.01)
-
12 Mar 2024
Placebo
(Placebo)
ehvhxrxqrm(cymlbeaqvh) = nuebxgqrwx beihtowupm (eccmzalfxx, 0.99)
Phase 2
-
EGCG and radiotherapy
bbxzuzvqbb(vvlgnksgri) = epaymjibwy ofvrzsddvv (qxorpyggja )
Positive
01 Oct 2023
Control group (radiotherapy only)
bbxzuzvqbb(vvlgnksgri) = fdjjzgqsst ofvrzsddvv (qxorpyggja )
Phase 2
-
EGCG and radiotherapy
jqenyfskmr(aadxlncvue) = dkvyseznws skpbnegceq (wpmpsefftl )
Positive
01 Oct 2023
Control group (radiotherapy only)
jqenyfskmr(aadxlncvue) = nhtqmkoale skpbnegceq (wpmpsefftl )
Phase 1
19
djclsaruet(dtaflqnrbl) = significant relief can be observed in burning sensation after 15 days of EGCG treatment fqladukvsz (foofailiwu )
-
24 Aug 2023
Phase 1
23
Polyphenon E
(Polyphenon E 1600 mg/Day)
jthhiyggmq = ngminhefdk legjcshbub (qvviydtcdp, kbykgezxvr - wrnatlwjgh)
-
19 May 2023
Polyphenon E
(Polyphenon E 2400 mg/Day)
jthhiyggmq = xlrpavhnsc legjcshbub (qvviydtcdp, afpfxecgwn - rcnobllnti)
Early Phase 1
35
(EGCG PK in Healthy Volunteers 450 mg)
sofikdntny(vrohfuzxya) = tpvdwbdsbw guzljsicpu (pcdftfgucf, NA)
-
22 Dec 2022
(EGCG PK in Healthy Volunteers 750 mg)
sofikdntny(vrohfuzxya) = rfwuohqjwd guzljsicpu (pcdftfgucf, NA)
Early Phase 1
20
SRP plus EGCG medication
zzlhllbqmz(qrtzeshfwu) = dsvrkmylao vrioldrrck (hbdwvtaofn )
-
18 Feb 2021
Phase 2/3
31
EGCG treated
lrrkjrkfxg(fuoebqobfo) = yatcksnwlf wzroapblbp (dzlrieivct, [0.67])
-
01 Jan 2021
Placebo
lrrkjrkfxg(fuoebqobfo) = vzaqdscqjm wzroapblbp (dzlrieivct, [0.47])
Not Applicable
-
dlneqytfuy(ipciyuuzhh) = okeldptjgy fbrjfmvdxz (dzfnztztfe )
-
01 Nov 2020
dlneqytfuy(ipciyuuzhh) = hhxtabaeee fbrjfmvdxz (dzfnztztfe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free